Physician profile
Michael E Grant
NPI 1316990781
$2,258.50
in general payments reported to CMS, 2019-2025
28 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $82.66 · 2022: $516 · 2023: $329 · 2024: $400 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $336.03 | 2022-2025 | Tarpeyo |
| Amgen INC. | $251.17 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $147.26 | 2019-2024 | Farxiga |
| Akebia Therapeutics INC | $145.05 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $143.32 | 2022-2024 | Terlivaz, Acthar |
| Novo Nordisk INC | $118.51 | 2023-2025 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $118.33 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $117.02 | 2019-2025 | Veltassa |
| Ardelyx, INC. | $107.83 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $104.98 | 2019-2024 | Nxstage System One, Liberty Select Cycler |
| Otsuka America Pharmaceutical, INC. | $88.08 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $84.87 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $69.52 | 2019-2024 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $63.39 | 2022-2025 | |
| Shire North American Group INC | $52.23 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $42.56 | 2019 | |
| Apellis Pharmaceuticals, INC. | $38.85 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $38.49 | 2020-2022 | |
| Travere Therapeutics, INC. | $31.08 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $23.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.42 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $19.41 | 2023 | Krystexxa |
| Nxstage Medical, INC. | $16.81 | 2019 | |
| Scpharmaceuticals INC. | $15.69 | 2025 | |
| Shield Therapeutics INC | $15.49 | 2025 | |
| Alexion Pharmaceuticals, INC. | $13.01 | 2019 | |
| Genentech USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.